At the Alzheimer’s Association International Conference® 2015 (AAIC®), Jeff Sevigny, M.D., senior director of clinical development at Biogen Idec, talks about findings from PRIME, the Phase 1b study of the experimental drug aducanumab.
At the Alzheimer’s Association International Conference® 2015 (AAIC®), Jeff Sevigny, M.D., senior director of clinical development at Biogen Idec, talks about findings from PRIME, the Phase 1b study of the experimental drug aducanumab.